vimarsana.com

Stroke Program At Mcmaster University News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bristol Myers, Bayer study results seed doubt about an emerging group of blood thinners

BioPharma

David risingerMukul sharmaBristol myersBristol myers squibbStroke program at mcmaster universityDive briefMyers squibbStroke programMcmaster universityClinical trials

Bristol Myers Squibb: Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy

~30% relative risk reduction seen in symptomatic ischemic strokes in three milvexian arms compared to placebo; dose response not observed for primary study objective No fatal bleeding and no increase

United statesBristol myers squibb janssenMukul sharmaBristol myers squibbXia fxiaAcademic research consortiumJanssen pharmaceuticals incAmerican heart association scientific sessionsEuropean society of cardiologyHamilton health sciencesMcmaster universityJanssen pharmaceutical companies of johnsonPopulation health research instituteExchange commissionStroke program at mcmaster universityMyers squibb

Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy

28.08.2022 - Bristol Myers Squibb (NYSE:BMY) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced results from the Phase 2 AXIOMATIC-SSP dose-ranging study of the .

United statesBristol myers squibb janssenMukul sharmaBristol myers squibbXia fxiaJanssen pharmaceutical companies of johnsonMcmaster universityAcademic research consortiumPopulation health research instituteAmerican heart association scientific sessionsExchange commissionEuropean society of cardiologyStroke program at mcmaster universityHamilton health sciencesHot lineEuropean society

Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy - Press Release

~30% relative risk reduction seen in symptomatic ischemic strokes in three milvexian arms compared to placebo; dose response not observed for primary

United statesBristol myers squibb janssenMukul sharmaBristol myers squibbPuneet mohanXia fxiaJanssen pharmaceuticals incAmerican heart association scientific sessionsEuropean society of cardiologyHamilton health sciencesMcmaster universityJanssen pharmaceutical companies of johnsonPopulation health research instituteMilvexian clinical developmentExchange commissionStroke program at mcmaster university

vimarsana © 2020. All Rights Reserved.